Skip to content

The Role of Fistula-tract Laser Closure in the Management of Perianal Fistula (FiLaC)

The Efficacy of Fistula-tract Laser Closure in the Management of Perianal Fistula

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12619000493145
Enrollment
10
Registered
2019-03-26
Start date
2019-06-01
Completion date
Unknown
Last updated
2019-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The research project is testing a new treatment for perianal fistula. The new treatment is called Fistula-tract Laser Closure (FiLaC), produced by Bio-litec ®. This treatment is approved by the Therapeutic Goods Administration for treatment of this condition. The aim of this study is to assess the efficacy of FiLaC in treating patients with perianal fistula disease. This includes success rate of the treatment, associated pain, and return to normal daily activities post-operation.

Interventions

The aim of FiLaC (produced by Bio Litec ®) is to gently remove the fistula tract without damaging the anal sphincter (important for faecal continence). FiLaC is administered by the treating surgeon. The approximate duration of the procedure is 30 minutes. A flexible, radially emitting laser fiber is inserted through the external fistula opening (skin opening) and positioned exactly using a pilot beam. Energy (1470nm) is then emitted radially into the fistula, with the epitheliaized tissue linin

The aim of FiLaC (produced by Bio Litec ®) is to gently remove the fistula tract without damaging the anal sphincter (important for faecal continence). FiLaC is administered by the treating surgeon. The approximate duration of the procedure is 30 minutes. A flexible, radially emitting laser fiber is inserted through the external fistula opening (skin opening) and positioned exactly using a pilot beam. Energy (1470nm) is then emitted radially into the fistula, with the epitheliaized tissue lining the tract being destroyed. It uses the surgical diode laser system (composed of aluminium) which is approved by the Therapeutic Goods Administration (TGA) of the Australian Government for treatment of this condition.

Sponsors

Dr Toufic El-Khoury
Lead SponsorIndividual

Study design

Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

- Age greater than or equal to 18 years old - Known perianal fistula disease

Exclusion criteria

- Pregnancy - Unable to consent or unwilling to consent to procedure - Crohn’s disease

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026